Overall, 21 of 21 patients with TP53 mutations (100%) versus 32 of 78 patients with wild-type TP53 (41%) achieved CR/CRi or a morphologic leukemia-free state (MLFS) with 10-day decitabine treatment [37]. Here, TP53 is linked to leukemia.